INTRODUCTION
Administration of human recombinant interleukin-2 (IL-2), alone or in combination with other cytokines, is currently under investigation for the immunotherapy of metastatic tumours. Tumour regression has been reported in patients with disseminated melanoma and renal cell carcinoma who received high-dose intravenous IL-2 alone or in combination with interferon-alpha (IFN-a). 1, 2 However, a syndrome of life-threatening adverse reactions such as disseminated vascular leakage, fluid retention and severe hypotension complicates treatment with IL-2. In addition, repetitive cytokine infusion results in a sepsis-like hemodynamic pattern including changes in systemic vascular resistance, heart rate and cardiac index. 3, 4 Many authors [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] have extensively demonstrated that sepsis syndrome is associated with an exacerbated production of inflammatory cytokines -tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6) and interleukin-1beta (IL-1b) -which are released into the systemic circulation. Although the presence of these cytokines in the circulation of septic patients clearly represents an overproduction, 15 it is not known whether these mediators reach the circulation in continuously or as short peaks after bacterial or immunological challenge. At present, there are no rapid clinical and/or laboratory predictive tests to anticipate the Through continuous cardiac output monitoring, we investigated the temporal relationship between hemodynamic changes and plasma cytokines in a cancer patient who developed collateral sepsis to immunotherapy. A 52-year-old male with metastatic renal cell carcinoma received interleukin-2 (IL-2) infusion completing 72 h of administration. The patient developed 3 sepsis-like states including systemic inflammatory response syndrome (SIRS), shock, and multiple organ dysfunction syndrome (MODS). Hemodynamic parameters including systemic vascular resistance index (SVRI), left ventricular stroke work index (LVSWI) and cardiac index (CI) were measured over 60 h. Peripheral blood was drawn when SVRI dropped 20% in the patient and plasma cytokines including TNF-a, IL-6 and IL-1b were measured using ELISA. After 60 h of immunotherapy, the patient showed a 63.4% decrease in SVRI, 54.5% decrease in LVSWI and 65.4% increase in CI. The evaluation of systemic cytokines revealed different kinetic patterns: (i) a sustained increase in TNFa levels through all 3 sepsis-like states; (ii) IL-6 increased preferentially during SIRS and shock, while up/down-responses were found during MODS; (iii) IL-1b was undetectable during the entire study period. A high temporal relationship between hemodynamic changes and plasma TNF-a, but not IL-6, was found. Although there are factors other than cytokines that can alter vascular resistance, this finding could represent an approach to evaluate the course of hemodynamia and probably the systemic cytokine expression after IL-2 administration in renal cancer.
intermittent appearance of cytokines in the circulation of these patients. Since cytokines act on the cardiovascular system affecting the microcirculation resulting in severe decrease of systemic vascular resistance, 16 and the technology is available for continuous measurement of cardiac output, [17] [18] [19] we investigated the temporal relationship between hemodynamic changes and plasma cytokine levels during a sepsis-like state in cancer immunotherapy. Here, we show new information based on a representative and well-characterized case report, where a high temporal correlation between hemodynamic parameters and plasma TNF-a was found during all courses of immunotherapy.
PATIENT, MATERIALS AND METHODS

Case report
A 52-year-old male patient arrived at the intensive care unit (ICU) of Las Condes Clinic, Santiago, with the diagnosis of metastatic renal cell carcinoma (mediastinum, lung and contralateral renal vein). The patient was enrolled in the immunotherapy protocol described by Negrier et al. 20 He received 9 doses of IL-2 (600,000 U/kg divided into 3 daily doses) completing 72 h of administration. The IL-2 administration strongly resembled sepsis since the patient developed a basal systemic inflammatory response syndrome (SIRS), followed by a shock stage at 34 h, and multiple organ dysfunction syndrome (MODS) 48 h after onset of the treatment. The temporal sequence of these three stages is in agreement with the standard definition established by the ACCP/SCCM consensus conference. 21 The protocol and consent form were approved by the Las Condes Clinic at Santiago, Chile Review Board on Ethics in Human Research.
Hemodynamic parameters
Hemodynamic monitoring was performed with a continuous cardiac output (CCO) monitor. The calibration of the CCO was carried out by the thermodilution method as described by Medin et al. 22 A pulmonary artery catheter (IntelliCath, Baxter Edwards Critical-Care, Irvine, CA, USA) was inserted through the external jugular vein and was connected to the CCO monitor. Measurements of hemodynamic variables included systemic vascular resistance index (SVRI), left ventricular stroke work index (LVSWI) and cardiac index (CI) which were performed over 60 h and calculated using standard formulae.
PLASMA CYTOKINES
Peripheral blood was only drawn when SVRI dropped more than 20%. Plasma was collected and kept at -20°C until assay. Cytokine determinations (TNF-a, IL-6 and IL-1b) were performed with specific, non-cross-reactive and sensitive commercially available enzyme-linked immunosorbent assay (ELISA) kits (Quantikine; R&D Sytems, Minneapolis, MN, USA). Measurements were done over 60 h in duplicate and performed the same day to avoid inter-assay variations. The detection limit of the ELISAs was 10 pg/ml.
RESULTS
Clinical data
IL-2 therapy in the patient induced hepatic changes from basal level to the end of the treatment, including increases in the concentrations of bilirubin (from 0.6 to 6.4 mg/dl), Creactive protein (from 21 to 139 mg/l) and fibrinogen (from 500 to 740 mg/dl). In addition, coagulation changes with decreased platelet counts (from 264,000 to 64,000 /cm 3 ) and increases in dimmer D were found. Under these conditions, the patient reached a hyperdynamic state with a decrease in blood pressure (from a basal level of median arterial pressure of 105 mmHg to 60 mmHg at 35 h after onset of therapy). This state required administration of vasoactive drugs (dopamine and phenylephrine). Slight mental disturbances (~13 Glasgow points) and persistent fever were also detected during the study period. Due to this, immunotherapy was discontinued and the sepsis-like symptoms improved. Hemodynamic parameters were normalized 48-72 h after suspension of IL-2 treatment. Negative blood culture at 6 days after IL-2 suspension ruled out sepsis in the patient. The patient was discharged after 6 days with stable hemodynamic and respiratory parameters, normal bilirubin levels, and conscience level.
Hemodynamic parameters
Hemodynamic parameters were monitored continuously for 60 h after IL-2 administration ( Fig. 1A-C) . A sustained decrease of SVRI from a basal level of 1898 to 694 dynes.s/cm 5 m 2 60 h later was observed (P < 0.001; Fig.  1A ). In this kinetic pattern, the larger drops in SVRI were observed at 2, 26, 50 and 58 h after onset of the immunotherapy. A 2.5-fold diminution in the LVSWI from a basal level of 74.5 to 33.4 gM/m 2 /cont 60 h later was observed in the patient (P < 0.01) ( Fig. 1B ). An increased CI was observed during the course of study, from a basal level of 4.15 to 6.34 l/min/m 2 (P < 0.02; Fig. 1C ).
Cytokine release patterns
The pattern of the three circulating cytokines in blood samples, drawn when SVRI failed during the immunotherapy treatment, is shown in Figure 2 . A high TNF-a concentration was detected in the circulation when the patient arrived at the ICU since the basal plasma level was 257 pg/ml; during the immunotherapy, sustained increases of TNF-a were observed, reaching the highest concentration (1295 pg/ml) when the MODS stage was attained (60 h). For plasma IL-6 measurements, a baseline concentration of less than 10 pg/ml (detection limit of ELISA) was observed; 2 h after onset of the immunotherapy, a significant elevated IL-6 level (359 pg/ml) was found (P < 0.001). Later, progressive increases were observed reaching the maximal peak 48 h at shock state, while up/down responses were found during MODS. Plasma IL-1b was not detected throughout the study period.
Relation between hemodynamics and plasma cytokines
To determine the timing of blood sampling during the sepsis-like state, we studied the possible correlation between hemodynamic parameters and circulating cytokine levels. Peak plasma concentrations of TNF-a were correlated inversely with changes in SVRI (r = 0.88; P < 0.001; Fig.  3 ). Similar correlations were obtained between plasma TNF-a and LVSWI (r = 0.92; P < 0.02) and CI (r = 0.94; P < 0.01). On the contrary, no temporal correlations were observed between plasma IL-6 or IL-1b and hemodynamic changes.
DISCUSSION
Renal cancer immunotherapy with recombinant IL-2 and/or IFN-a are the only drugs that have been shown to induce tumor regression in some patients, 20, 23 although repetitive infusion results in sepsis-like hemodynamic changes. 3, 4 Through continuous cardiac output monitoring, we demonstrated a temporal relationship between hemodynamic changes and plasma cytokine levels during a sepsis-like state in a cancer patient receiving IL-2
Continuous cardiac output and hemodynamic monitoring: cancer immunotherapy 93 The TNF-a kinetic pattern showed a high basal concentration with a progressive increase during the course of sepsis-like evolution, reaching an extreme level of 1295 pg/ml at the MODS stage. Plasma IL-6 showed a sinuous pattern from undetectable basal level to maximal peak registered 48 h at shock stage. IL-1b values did not show changes in any of the three stages. therapy. Although increasing concentrations of TNF-a and IL-6 were observed in the sepsis-like hemodynamic pattern, the best correlation was between SVRI and plasma TNF-a concentration throughout the immunotherapy period.
We used continuous monitoring to measure the hyperdynamic parameters. This methodology is safer than the intermittent thermodilution cardiac output and allows a better evaluation and control of the hemodynamia tendency. [17] [18] [19] After 60 h of immunotherapy, the patient showed a 63.4% decrease in SVRI, 54.5% decrease in heart rate and 65.4% increase in cardiac index. The cardiovascular abnormalities associated with IL-2 therapy in the patient with metastatic renal cell carcinoma agree with previous reports. [1] [2] [3] [4] 24 Treatment with IL-2 induced 3 transitory and progressive overlapping sepsis-like stages in the patient (SIRS, shock, and MODS), whose clinical picture disappeared when immunotherapy was suspended. During this period, the evaluation of systemic cytokines revealed different kinetic patterns: (i) a maintained increase of TNF-a through all 3 sepsis-like states; (ii) IL-6 increased preferentially during SIRS and shock, while up/down responses were found during MODS; and (iii) undetectable IL-1b levels were found throughout the study period. Although there are factors other than cytokines that can alter vascular resistance, this finding could represent an approach to evaluate the course of hemodynamia and probably systemic cytokine expression after IL-2 administration in renal cancer.
In relation to sepsis evolution, measurement of systemic cytokines in random blood samples obtained periodically reflect poorly what is going on at the local level. Previous reports indicate that circulating cytokines represent the 'tip of the iceberg', 15 while determination of cell-associated cytokines constitutes a better approach to assessing their production at local areas of inflammation/infection or injury. 5, 25 Here, results of our SIRS model suggest that plasma TNF-a appears in the circulation in parallel with hemodynamic changes in the patient. In fact, we found a very high temporal correlation between three hemodynamic parameters (SVRI, LVSWI, CI) and plasma TNF-a throughout immunotherapy. Swaveling et al. 26 reported high plasma TNF-a levels and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-a, IFN-g and maphalan. However, these authors only found a transitory correlation between plasma TNF-a concentration and SVRI (r = 0.49; P < 0.01) when the plasma cytokine reached the highest level.
Monitoring by continuous cardiac output could also help to define the optimal 'time of sampling', which in most critically ill patients is not known. The high temporal correlation between hemodynamic changes and plasma TNF-a described in this case report may represent an approach to evaluate the course of the sepsis-like state that develops collaterally to IL-2 administration in renal cancer. Further studies are needed to clarify if expression of circulating cytokines in the plasma could also be monitored by continuous cardiac output in other sepsis models and/or systemic inflammation. 
